Everything in the NHS changed in March when national and local leaders acted to prepare for the rapid […]
Agreement covers protein-alkylating, tumour-activated pro-drug payload series for ADC development
Company signs deals with two specialist pharmaceutical manufacturers
Participant in phase III study developed unexplained illness
Updated Date: Tue, 06 Oct 2020 00:00:00 EDT
Updated Date: Tue, 06 Oct 2020 00:00:00 EDT
Updated Date: Tue, 06 Oct 2020 00:00:00 EDT
Updated Date: Tue, 06 Oct 2020 00:00:00 EDT
Updated Date: Tue, 06 Oct 2020 00:00:00 EDT
